10-Q: OS Therapies Reports Strong OST-HER2 Trial Data, Faces Liquidity

OS Therapies announced positive two-year survival data for its lead cancer therapy OST-HER2, while reporting increased losses and a going concern warning.

Summary

• OS Therapies is a clinical-stage biopharmaceutical company focused on treatments for Osteosarcoma and other solid tumors.
• The company's lead product candidate, OST-HER2, achieved its primary endpoint in a Phase IIb clinical trial with statistical significance in Q1 2025.
• Final two-year overall survival data for OST-HER2 (October 2025) showed 75% survival (27 of 36 evaluable patients) compared to 40% in historical control patients (p < 0.0001).
• Regulatory meetings with the FDA, MHRA, and EMA indicated that overall survival, supported by biomarker data, may be considered for conditional marketing authorization.
• The company acquired HER2 Assets from Ayala Pharmaceuticals, Inc. on April 9, 2025, for $8,000,000 (cash and common stock), terminating a previous license agreement and reducing future royalty obligations.
• Net loss for the nine months ended September 30, 2025, was $15,293,011, a significant increase from $5,891,704 for the same period in 2024.
• Research and Development expenses increased to $7,563,988 for the nine months ended September 30, 2025, from $1,968,591 in 2024.
• General and Administrative expenses rose to $9,153,821 for the nine months ended September 30, 2025, from $1,878,831 in 2024.
• Cash balance as of September 30, 2025, was $1,876,626, down from $5,533,527 at December 31, 2024.
• The company raised approximately $7,103,000 in gross proceeds from a PIPE financing (December 2024 and January 2025) and approximately $6,398,358 from warrant exercise inducement and exchange offers (July and September 2025).
• An At-The-Market (ATM) Equity Offering Program was established on August 8, 2025, to sell up to $18,000,000 of common stock, with $384,888 in gross proceeds from 189,600 shares sold as of the filing date.
• Stockholders approved increasing authorized common stock from 50 million to 150 million, amending the 2023 Incentive Compensation Plan, and a shareholder rights agreement on October 21, 2025.

Sentiment

Score: 5

Explanation: The strong clinical trial results for OST-HER2 are a significant positive, indicating potential for regulatory approval and future revenue. However, this is heavily offset by substantial and increasing net losses, high cash burn, a critical 'going concern' warning, and ineffective internal controls. The company's future is highly dependent on successful and continuous capital raises, creating a balanced but precarious sentiment.

Positives

• OST-HER2 Phase IIb clinical trial achieved its primary endpoint with statistical significance in Q1 2025.
• Final two-year overall survival data for OST-HER2 showed 75% survival (27 of 36 patients) compared to 40% in historical control patients (p < 0.0001), indicating strong efficacy.
• Regulatory agencies (FDA, MHRA, EMA) indicated that overall survival, supported by biomarker data, may be considered an appropriate clinical endpoint for conditional marketing authorization.
• Acquisition of HER2 Assets from Ayala Pharmaceuticals terminated a prior license agreement, eliminating $3,500,000 in BLA approval payments and $16,500,000 in sales milestone payments, and reducing royalty consideration from 10% to 1.5% of net sales.
• Successful capital raises through PIPE financing ($7.1 million gross) and warrant exercise inducement offers ($6.4 million gross) provided necessary funding.

Negatives

• Net loss for the nine months ended September 30, 2025, significantly increased to $15,293,011 from $5,891,704 in the prior year period.
• Operating losses for the nine months ended September 30, 2025, were $(16,717,809), a substantial increase from $(3,847,422) in the prior year.
• Cash balance decreased significantly to $1,876,626 as of September 30, 2025, from $5,533,527 at December 31, 2024.
• The company has incurred net losses since inception and has negative operating cash flows, raising substantial doubt about its ability to continue as a going concern.
• Disclosure controls and procedures were deemed not effective as of September 30, 2025, due to a lack of segregation of duties and insufficient written policies and procedures for accounting, information technology, and financial reporting.
• Accounts payable increased significantly to $3,374,287 as of September 30, 2025, from $1,662,068 at December 31, 2024.

Risks

• The company's ability to continue operations is dependent on obtaining additional capital through public or private equity financing, with no assurances of success.
• Issuance of shares in connection with offerings and potential resale by holders could result in substantial dilution to existing stockholders and negatively affect the market price of common stock.
• Sales of a substantial number of shares under the At-The-Market (ATM) Equity Offering Program could cause the market price of common stock to decline.
• Investors purchasing shares through the ATM program at different times may pay different prices and experience varying levels of dilution and investment outcomes.
• The company's disclosure controls and procedures are not effective due to limited personnel and insufficient written policies, which could lead to undetected misstatements.
• An arbitration hearing regarding a claim for underwriter compensation from a former investment advisor concluded on November 7, 2025, with a formal ruling expected in February 2026, which could have an adverse outcome.

Future Outlook

The company expects to submit a conditional Marketing Authorization Application (MAA) to the MHRA in December 2025, a Biologics License Application (BLA) under the FDA's Accelerated Approval Program in January 2026, and an MAA to the EMA in Q1 2026. If FDA approval is successful for OST-HER2 in Osteosarcoma, the company intends to evaluate its potential use, alone and in combination with HER2 targeting antibodies, in other solid tumors like breast, esophageal, and lung cancers. The company also plans to investigate clinical indications for its OST-tADC platform in Osteosarcoma and other solid tumors. Biomarker activation results from the Phase IIb trial are expected in November 2025. The company is currently seeking to raise additional capital through public or private equity financing to fund future operations.

Management Comments

• "We believe the results [of OST-HER2 Phase IIb trial], combined with the products safety profile and unmet clinical need, support the potential for regulatory approval from the FDA."
• "Representatives from these agencies [FDA, MHRA, EMA] indicated that overall survival, when supported by biomarker data, may be considered an appropriate clinical endpoint to support conditional marketing authorization."
• "We are currently analyzing patient samples from our Phase IIb trial to assess potential correlations between clinical outcomes and immune system biomarker activation, with results expected in November 2025."
• "For the foreseeable future, the Company’s ability to continue its operations is dependent upon its ability to obtain additional capital."
• "The Company is currently seeking to raise additional capital through a public or private financing of equity; although there can be no assurances the Company will be successful in such a campaign."

Industry Context

OS Therapies operates in the highly competitive and capital-intensive biopharmaceutical sector, specifically targeting rare and aggressive cancers like Osteosarcoma, which has a significant unmet medical need. The positive Phase IIb clinical trial results for OST-HER2, showing a substantial improvement in two-year overall survival compared to historical controls, position the company favorably for potential regulatory approvals. The strategic acquisition of HER2 assets and the development of the OST-tADC platform indicate a broader strategy to leverage its technology across various HER2-expressing solid tumors, aligning with industry trends towards targeted immunotherapies and antibody-drug conjugates. However, the company's significant operating losses and 'going concern' warning highlight the inherent financial challenges faced by clinical-stage biotech companies reliant on external funding to advance their pipelines.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• An arbitration hearing concluded on November 7, 2025, for a claim brought by a former investment advisor seeking underwriter compensation for the company's initial public offering and subsequent equity offerings. A formal ruling is expected in February 2026.

Related Party Transactions

• Payroll advances to CEO Paul Romness totaled $41,852 as of September 30, 2025, expected to be repaid in 2025.
• Accounting fees of $15,925 for the period ended September 30, 2025, were owed to Shore Accountants MD Inc., a firm 100% owned by CFO Christopher Acevedo.

Stakeholder Impact

• **Shareholders:** Potential for significant dilution from ongoing and future equity raises (PIPE, warrant exercises, ATM offering) and increased authorized shares. The 'going concern' warning poses a substantial risk to investment value. Positive clinical trial results offer potential upside if regulatory approvals are secured.
• **Employees:** Continued operations are dependent on capital raises, which could create uncertainty. Stock-based compensation plans are being expanded, potentially benefiting employees.
• **Customers (future):** Successful regulatory approvals for OST-HER2 could bring a new treatment option for Osteosarcoma patients, addressing an unmet medical need.
• **Creditors:** The 'going concern' warning indicates increased risk regarding the company's ability to meet its financial obligations without further capital.

Next Steps

• Analyze patient samples from the Phase IIb trial to assess potential correlations between clinical outcomes and immune system biomarker activation, with results expected in November 2025.
• Submit a conditional Marketing Authorization Application (MAA) to the MHRA in December 2025.
• Submit a Biologics License Application (BLA) under the FDA's Accelerated Approval Program in January 2026.
• Submit an MAA to the EMA in the first quarter of 2026.
• If FDA approved, evaluate OST-HER2's potential use, alone and in combination with HER2 targeting antibodies, in other solid tumors (breast, esophageal, lung cancers).
• Investigate clinical indications for the OST-Tunable Drug Conjugate (OST-tADC) platform in Osteosarcoma and other solid tumors.
• Close out and report on the OST-504 (previously ADXS-504) prostate cancer study.
• Initiate AI-driven next-generation tADC product candidate modeling.
• Obtain a formal ruling from the arbitration hearing regarding a former investment advisor's claim, expected in February 2026.
• Continue seeking additional capital through public or private equity financing.

Key Dates

Recommendation

The company presents a high-risk, high-reward profile. The exceptionally strong Phase IIb clinical trial results for OST-HER2, demonstrating a significant improvement in two-year overall survival for Osteosarcoma, are a major positive and suggest strong potential for regulatory approval and future commercialization. This fundamental progress in its lead asset is compelling. However, the company's severe liquidity issues, substantial and increasing net losses, and explicit 'going concern' warning create significant financial instability. While recent capital raises provide some runway, the continuous need for financing and the ineffective internal controls introduce considerable operational and financial risk. An investor should 'hold' to monitor the progress of regulatory submissions and biomarker data, which could be catalysts, but also be prepared for potential further dilution and the inherent risks associated with a company facing a going concern doubt. A 'buy' would be premature given the financial fragility, and a 'sell' would disregard the promising clinical data.

Keywords

Osteosarcoma, OST-HER2, Cancer Immunotherapy, Biopharmaceutical, Clinical Trial, SEC Filing, 10-Q, Oncology, HER2 Assets, Biologics License Application, Marketing Authorization Application, Going Concern, Capital Raise, ATM Offering, Warrant Exercise, Corporate Governance